Thursday, 23 July 2020

Glenmark's Favipiravir shows positive results in Phase-3 clinical trials

Pharmaceutical giant Glenmark on Wednesday said its Phase-3 clinical trials of antiviral drug Favipiravir showed improvement in mild and moderate novel coronavirus patients. In a statement on Wednesday, Glemnmark said Covid-19 patients administered with Favipiravir reported faster clinical cure and viral clearance as compared to those with routine care.


No comments:

Featured Post

Hindenburg Crashes without any cogent reason

TODAY'S ECONOMICS once again proved correct  Esteemed readers will recollect that earlier TODAY'S ECONOMICS had in its editorial (D...